Roche announced today that data from three Phase III studies of its investigational medicine OCREVUS ® (ocrelizumab)– the OPERA I and OPERA II studies in relapsing multiple sclerosis (RMS) and the ORATORIO study in primary progressive multiple sclerosis (PPMS) – were published in the 21 December 2016 online issue of the New England Journal of Medicine (NEJM). (Source: Roche Media News)

Read full article on